India's mega-gliptins battle: shifting sands?

Brace yourself for more action in India's highly competitive dipeptidyl peptidase-4 (DPP-4) inhibitor market. Be it the vildagliptin versus sitagliptin tug-of-war or teneligliptin's price war cry or then second brand successes, there appears to be more in store in the space.